1. Scrip
  2. >>Business

Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability

 
• By Anju Ghangurde

The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.

Raymond De Vre
Raymond De Vré, Dr Reddy’s Biologics Business Unit Global Head

An estimated $75bn worth of blockbuster biologic products are expected to be exposed to biosimilar competition by 2025 and Indian firms like Dr. Reddy's Laboratories Ltd. are upbeat about emerging prospects in the US, amid signs of improving adoption of such products and coverage by insurers and payers.

The strong performance of biosimilar pegfilgrastim in the US, especially Coherus BioSciences Inc.’s Udenyca (pegfilgrastim-cbqv), with “rapid and high...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 
• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

More from Scrip

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.